NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

DCVax-l target hundreds of different antigens, whereas that Car-T therapy, as shown in the quote below, only targets two. That is why Car-T is “transient.” Tumor escape. The Car-T cynical response is to say oh well, let’s just add chemo now. So essentially, the Car-T spreads the cancer cells with non-responding antigens. The cynical approach of just divvying up antigens for various companies to make money without curing the problem is the problem.

Typically, CAR T cells target a single antigen or single tumor marker protein on the tumor cells. This treatment strategy has been highly effective in some forms of blood cancers that have a common antigen across tumor cells, such as lymphoma, but it has yet to be translated to solid tumors, which have a more diverse population of cells.
To address this challenge, Maus and Choi developed a second-generation treatment known as CAR-TEAM cells (T Cell Engager Antibody Molecules), which have a dual targeting mechanism that enables them to target two different proteins expressed by glioblastoma cells.

All three patients in the initial trial showed dramatic but transient reductions in tumor size in imaging scans taken after their treatments.

https://news.harvard.edu/gazette/story/2024/03/novel-teamwork-promising-results-for-glioblastoma-treatment/